Literature DB >> 16819666

[Multiple sclerosis. An update with practical guidelines for ophthalmologists].

T Ziemssen1, H Wilhelm, F Ziemssen.   

Abstract

Multiple sclerosis (MS) is the most frequent chronic inflammatory disease of the central nervous system. Mostly young adults present with a variety of different symptoms due to the multiple localisations of the inflammatory lesions. Up to one-third of MS patients experience symptoms of optic neuritis as the initial symptom. That is the reason why the ophthalmologist often is the first physician contacted by patients later on diagnosed with MS. Today, it is known that there is already a significant irreversible axonal loss in MS patients progressing from the beginning of the disease. Therefore early, diagnosis and application of available therapeutic options are necessary for the patient's benefit. The therapeutic aim in early immunomodulatory treatment is to decrease the number of relapses and to slow down the development of clinical disability. This interdisciplinary overview presents guidelines for the clinical routine: how to assess the individual risk of each patient and how to treat the patient in accordance with current pathogenic, diagnostic and therapeutic knowledge.

Entities:  

Mesh:

Year:  2006        PMID: 16819666     DOI: 10.1007/s00347-006-1368-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  75 in total

1.  [Randomized controlled trial of high-dose peroral methylprednisolone in attacks of multiple sclerosis].

Authors:  F Sellebjerg; J L Frederiksen; P M Nielsen; J Olesen
Journal:  Ugeskr Laeger       Date:  1999-11-29

Review 2.  Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

3.  The 5-year risk of MS after optic neuritis.

Authors:  G Francis
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

4.  Suspicion of multiple sclerosis. To tell or not to tell?

Authors:  W Sencer
Journal:  Arch Neurol       Date:  1988-04

5.  Isolated cranial nerve palsies in multiple sclerosis.

Authors:  F Thömke; E Lensch; K Ringel; H C Hopf
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-11       Impact factor: 10.154

6.  Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial.

Authors:  J L Keltner; C A Johnson; J O Spurr; R W Beck
Journal:  Arch Ophthalmol       Date:  1994-07

7.  Optic neuritis: correlation of pain and magnetic resonance imaging.

Authors:  Hilary E Fazzone; Daniel R Lefton; Mark J Kupersmith
Journal:  Ophthalmology       Date:  2003-08       Impact factor: 12.079

Review 8.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.

Authors:  M Andersson; J Alvarez-Cermeño; G Bernardi; I Cogato; P Fredman; J Frederiksen; S Fredrikson; P Gallo; L M Grimaldi; M Grønning
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

9.  Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI.

Authors:  P A Brex; K A Miszkiel; J I O'Riordan; G T Plant; I F Moseley; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-03       Impact factor: 10.154

Review 10.  The needs and experiences of caregivers of individuals with multiple sclerosis: a systematic review.

Authors:  L P McKeown; A P Porter-Armstrong; G D Baxter
Journal:  Clin Rehabil       Date:  2003-05       Impact factor: 3.477

View more
  2 in total

1.  Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model.

Authors:  Anna T Wilmes; Sabrina Reinehr; Sandra Kühn; Xiomara Pedreiturria; Laura Petrikowski; Simon Faissner; Ilya Ayzenberg; Gesa Stute; Ralf Gold; H Burkhard Dick; Ingo Kleiter; Stephanie C Joachim
Journal:  J Neuroinflammation       Date:  2018-06-14       Impact factor: 8.322

2.  Astrocytic YAP protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model through TGF-β signaling.

Authors:  Qian Wu; Xuemeng Miao; Jingjing Zhang; Ludan Xiang; Xiuchun Li; Xiaomei Bao; Siyu Du; Mianxian Wang; Shuangda Miao; Yiren Fan; Wei Wang; Xingxing Xu; Xiya Shen; Danlu Yang; Xiwu Wang; Yuanyuan Fang; Lixin Hu; Xuyi Pan; Haoru Dong; Hui Wang; Ying Wang; Jia Li; Zhihui Huang
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.